Coca-Cola Europacific Partners vs Keurig Dr Pepper
CCEP and KDP side by side, both in beverages. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CCEP and KDP compare
Keurig Dr Pepper grew revenue faster over the last twelve months (27.5% versus 2.3% for Coca-Cola Europacific Partners).
Coca-Cola Europacific Partners keeps more of each dollar of sales as profit, with a net margin of 9.3% compared with 7.1% at Keurig Dr Pepper.
Keurig Dr Pepper pays a dividend yielding 2.6%; Coca-Cola Europacific Partners does not pay one.
Coca-Cola Europacific Partners scores higher on the StockData Score (10 against 8 for Keurig Dr Pepper), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CCEP | KDP |
|---|---|---|
| Size and price | ||
| Market cap | – | $48.8B |
| Share price | $113.22 | $35.84 |
| Change, 1 year | 27.8% | 32.0% |
| Change, 5 years | 105% | −1.5% |
| Beta (5Y) | 0.52 | 0.31 |
| Employees | 39K | 31K |
| StockData Score | ||
| Total score | 10 (better) | 8 |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 6 (better) | 1 |
| Health score | 2 (better) | 0 |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | – | 36.2× |
| P/S | – | 2.4× |
| P/B | – | 1.9× |
| EV/EBITDA | – | 25.0× |
| P/FCF | – | 24.8× |
| PEG | – | 2.44 |
| FCF yield | – | 4.0% |
| Fair value | – | $25.87 |
| Margin of safety | – | −38.5% |
| Growth | ||
| Revenue growth (TTM) | 2.3% | 27.5% (better) |
| Revenue growth, 5Y average | 14.5% (better) | 7.4% |
| Net income growth (TTM) | 37.0% (better) | −7.1% |
| EPS growth (TTM) | 38.3% (better) | −11.6% |
| EPS growth, 5Y average | 31.3% (better) | 10.5% |
| Profitability | ||
| Gross margin | 35.6% | 49.4% (better) |
| Operating margin | 13.4% | 16.2% (better) |
| Net margin | 9.3% (better) | 7.1% |
| FCF margin | 10.5% (better) | 9.8% |
| Return on equity | 23.8% (better) | 5.7% |
| Return on invested capital | 12.0% (better) | 5.3% |
| Financial health | ||
| Debt / equity | 1.36 | 1.20 (better) |
| Net debt / EBITDA | 3.50 (better) | 8.73 |
| Interest coverage | 9.1× | – |
| Current ratio | 0.80 (better) | 0.48 |
| Altman Z-score | – | 0.84 |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 2.6% |
| Payout ratio | – | 87.5% |
| Years of dividend growth | – | 5 |
| Dividend growth, 5Y average | – | 8.9% |
| Shareholder yield | – | 2.6% |
| Ownership | ||
| Held by institutions | 34.4% | 106% |
| Held by insiders | 17.6% | 4.7% |
| Insider net buying, 12 months | – | −$1.1M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 5.7% |
Go deeper
- CCEP stock overview
- CCEP income statement
- CCEP valuation and score
- KDP stock overview
- KDP income statement
- KDP valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.